PMH37 - Cost-Effectiveness of Injectable Atypical Long-Acting Antipsychotics for Chronic Schizophrenia in Poland

Abstract

Objective: In order to determine the cost-effectiveness of paliperidone palmitate (PP-LAI), a long-acting injectable formulation, indicated for once-monthly injections as antipsychotic thera py, it was compared with risperidone, a long-acting, injectable (RLAI) and biweekly agent, admi nistered for treatment of chronic schizophrenia in Poland, as perceived from the perspective of the National Health Fund (NHF). Methods: We adapted a 1-year decision tree model to the Polish healthcare system with literature-derived and clinical expert inputs. The compared drugs included PP-LAI, a new treatment option of antipsychotic therapy, and RLAI, the established treatment for Polish patients. Clinical rates were derived from published trials. Model outputs included expected cost per patient, as well as the rates of hospitalization, emergency room visits, days free of symptoms and quality-adjusted life-years (QALYs). One-way sensitivity analyses were applied to major inputs. All the inputs were also simultaneously varied in probabilistic sensitivity analyses.